INTERFERON ALFA-2b (Interferon alfa-2b)

     Pharmacological Effects: Interferon. Represents Highly recombinant protein with molecular mass 19300 Dalton. Received a clone by hybridization E.coli bacteria gene plasmids human cells, Crypto synthesis of interferon. Unlike interferon alfa-2a Arginine is in a position 23. Provides antiviral effect, due to interaction with specific receptors and membrane induced RNA synthesis and ultimately protein. The latter in turn prevent the virus reproduction or his release. Has immunomoduliruyuschey activity, which involves the activation of phagocytosis, promoting education and limfokinov antibodies. Provides antiproliferativnoe effect on the tumor cells.

     Pharmacokinetics: When in / m a 70% goes to systemic blood flow. Biotransformiruetsya mostly in the kidneys and a small extent in the liver.

Interferon alfa-2b derived from the body's kidneys.

     Indications: Chronic hepatitis B, chronic hepatitis C, mushroom Mycobacterium, the primary T-cell lymphosarcoma, volosato- cell leukemia, mielomnaya disease (generalized form), chronic mieloleykoz, malignant Melanoma, bladder cancer (superficial located), bazalno- cell carcinoma, pointed kondilomatoz, Kaposi sarcoma (including with AIDS), nehodzhkinskie Lymphoma (in a combination therapy).

     Contraindications: Heavy heart disease; Serious violations as liver and / or kidney; Epilepsy and / or serious violations TSNS functional; Chronic hepatitis threatened development of liver cirrhosis; Liver disease in the phase decompensation; Against the backdrop of chronic hepatitis or after prior therapy immunosuppressants ( with the exception of the abolition of short-term corticosteroid therapy); autoimmune hepatitis; autoimmune diseases in history; transplant recipients of immunodeficiency; previous thyroid disease; increased sensitivity to interferon alfa-2b.

     Application of pregnancy is possible in cases where the expected benefits to the mother than the potential risk to the fetus. If necessary, use during lactation should decide on the termination of breast-feeding.

Women of childbearing age in the period of interferon alfa-2b should be reliable methods of contraception.

     Side Effects: Grippopodobny syndrome: fever, tiredness, arthralgia, general malaise, raising sweat.

On the part of the digestive system: nausea, anorexia, drought in the mouth; Seldom-diarrhoea, violations taste sensations, pain, increased activity transaminaz liver, the level of bilirubin.

By TSNS: asthenia, headaches, dizziness, depression, irritability, sleep violations, that the ability to focus, paresthesia, anxiety, neuropathy.

From the cardiovascular system: changes in AD, tachycardia; Seldom-tranzitornaya cardiomyopathy.

On the part of the respiratory system: little-cough, pharyngitis, lung infiltraty, pnevmonity pneumonia.

Other: nasal bleeding, reduced libido, a violation of thyroid function.

     Special instructions: Do not be applied to patients with mental disorders in history.

To use caution in patients with lung diseases in history (including with chronic obstructive lung diseases), with sugar diabetes with a tendency to ketoacidosis, high blood downsizing (including physiotherapists in the lung and pulmonary arteries in history) mielodepressii serious condition.

Before and systematically during treatment should be monitoring liver function, peripheral blood picture, biochemical indicators blood kreatinina. During treatment should be adequate hydration body.

In patients with chronic hepatitis C during treatment should monitor tireotropnogo hormone levels. In chronic hepatitis B, involving reducing liver synthetic function (which is to reduce or increase the level of albumin protrombinovogo time), should assess the expected benefits and possible risks of therapy.

The application if it is accompanied by chest justified in cases where the expected benefits of therapy over the potential risks.

In an accompanying sugar diabetes, or arterial hypertension before and during treatment required inspection Eye floor.

When referring to a chronic disorder of heart failure, heart attack miokarda and / or pre-existing arrhythmia treatment or interferon alfa-2b should be under strict supervision of a doctor.

The impact on the ability to drive vehicles and machinery management

At the beginning of therapy should refrain from potentially hazardous activities that require attention, psychomotor quick reactions until the stabilization of interferon alfa-2b.

Interferon alfa-2b in the form of powder injection and solution for injection ZHNVLS included in the list.

     Drug interactions: Interferony can enhance neurotoxic, or mielotoksicheskoe kardiotoksicheskoe of drugs naznachavshihsya before or simultaneously with it.

     Dosing and Administration: Individual, depending on the evidence and treatment schemes. Adults with volosato- in cell leukemia / m or p / to impose on 2 million IU / m2 three times a week. In Kaposi sarcoma and 30 million IU / m2 three times a week.

Materials allowed to copy only with the active hyperlink to the handbook of medicines